Share on LinkedInShare on LinkedIn

ARTICLE · 09 JUNE 2026

Cannabis M&A After Rescheduling: Are You Ready For What Comes Next?

The U.S. Department of Justice's April 2026 rescheduling of medical cannabis to Schedule III has fundamentally altered the regulatory and financial landscape for cannabis businesses.

United StatesGovernment, Public Sector

Key Takeaways:

  • The U.S. Department of Justice rescheduled state-licensed medical cannabis and FDA-approved cannabis products to Schedule III on April 23, 2026, marking a structural shift in federal tax and regulatory treatment.
  • Cannabis rescheduling could accelerate M&A activity in 2026 and beyond by potentially improving cash flow, reopening equity markets, and reshaping buyer and seller expectations — though adult-use cannabis remains under review. 
  • As capital returns, buyers will become more selective, prioritizing clean financials, defensible earnings, and clear visibility into tax and compliance risk.

—

The cannabis industry has entered a new regulatory phase. On April 23, 2026, the U.S. Department of Justice officially rescheduled state-licensed medical cannabis and FDA-approved cannabis products from Schedule I to Schedule III. This marks a significant shift in federal treatment of cannabis-related businesses and begins to reshape how the industry is taxed,

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from